<DOC>
	<DOCNO>NCT01290406</DOCNO>
	<brief_summary>This open label single arm study investigate safety efficacy BEZ235 adult woman endometrial carcinoma whose disease progress ( recur ) first-line antineoplastic treatment advance endometrial carcinoma .</brief_summary>
	<brief_title>BEZ235 Trial Patients With Advanced Endometrial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Female ≥ 18 year Histological confirm diagnosis advance endometrial carcinoma available tissue specimen , either archival tissue fresh formalin fix tumor biopsy Objective radiologically confirm progression disease prior firstline treatment Recovery ( grade ≤ 1 ) clinically significant toxicity relate prior therapy ( except alopecia ) adequate bone marrow organ function At least one measurable lesion per RECIST Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Previous treatment PI3K and/or mammalian Target Of Rapamycin ( mTOR ) inhibitor More one line prior treatment advance metastatic disease Active uncontrolled symptomatic Central Nervous System ( CNS ) metastases Concurrent malignancy malignancy last 3 year prior start study treatment Wide field radiotherapy ≤ 28 day limit field radiation palliation ≤ 14 day prior enrollment study Active cardiac disease ( e.g . Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % , QT interval correct heart rate ( QTcF ) &gt; 480 msec screen Electrocardiogram ( ECG ) , unstable angina pectoris , ventricular , supraventricular nodal arrhythmia ) Inadequately control hypertension Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BEZ235 Drugs know risk induce Torsades de Pointes , moderate strong inhibitor inducer CYP3A4 , warfarin coumadin analogue , Luteinizing HormoneReleasing Hormone ( LHRH ) agonists Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Endometrial cancer ,</keyword>
	<keyword>uterine cancer ,</keyword>
	<keyword>PI3K ,</keyword>
	<keyword>mTOR ,</keyword>
	<keyword>target therapy</keyword>
</DOC>